MRNA YOLO. Thanks for donating your options to me so cheap and your shares.
Author is bullish on MRNA and has acquired cheap options and shares, betting against predictions of bankruptcy. The position implies conviction that the stock will recover.
Past performance does not predict future results. Informational only, not investment advice.
Author is bullish on MRNA and has acquired cheap options and shares, betting against predictions of bankruptcy. The position implies conviction that the stock will recover.
Author is bearish on Moderna and holding a short position, expecting the stock to decline to at least $150. The position is at risk of margin call if the stock continues higher.
MRNA sold off sharply on rumors of an offering that materialized. Author is closing a put position at open, implying the move down has already occurred and profit is being taken.
Author maintains a long-term bullish conviction in MRNA despite a substantial recent gain. The company is viewed as a value opportunity with strong fundamentals, evidenced by the author's decision to retain the bulk of their position (19% of portfolio) even after realizing $50k in gains.
Author executed a short-term put trade on Moderna, betting on IV crush or a quick reversal for profits on opening.
Moderna has cleared major FDA and regulatory hurdles; Phase 3 Intismeran data coming summer with fall FDA application should drive stock from ~$50 to $100+ on positive data. High short interest (~20%) creates potential for a squeeze to $200–300.
End of results.